Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Market Outperform recommendation. Analyst Price Forecast Suggests 219.11% ...

JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

AI is evolving rapidly with recent breakthroughs making it more accessible and efficient than ever. Smaller, cost-effective ...

JMP Securities analyst Constantine Davides raised the firm’s price target on Option Care Health (OPCH) to $35 from $30 and ...

JMP Securities raised the price targets on Cloudflare (NET) and CyberArk Software (CYBR), while highlighting an industry ...

Investing.com -- JMP Securities initiated coverage on digital infrastructure companies on AI related spending boom. Over the next five years, over $1 trillion in investments is expected ...

Investing.com -- JMP Securities initiated coverage on digital infrastructure companies on AI related spending boom. Over the next five years, over $1 trillion in investments is expected, driven by AI, ...

On Monday, JMP Securities maintained its Market Outperform rating on Century Casinos shares (NASDAQ:CNTY) with a set price target of $5.00. The firm highlighted Century Casinos' potential as an ...